TrialJournal of neuro-oncology2017

Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma.

Surasak Phuphanich et al.PubMed ↗Publisher ↗

No numbers read from the abstract.